These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8970044)

  • 21. Eosinophilia-myalgia syndrome in Wisconsin.
    Butler JC; Davis JP
    Wis Med J; 1990 Dec; 89(12):687-91. PubMed ID: 2293489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eosinophilia myalgia syndrome.
    Blackburn WD
    Semin Arthritis Rheum; 1997 Jun; 26(6):788-93. PubMed ID: 9213377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tryptophan metabolism via the kynurenine pathway in patients with the eosinophilia-myalgia syndrome.
    Silver RM; McKinley K; Smith EA; Quearry B; Harati Y; Sternberg EM; Heyes MP
    Arthritis Rheum; 1992 Sep; 35(9):1097-105. PubMed ID: 1418026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eosinophilia-myalgia syndrome not associated with L-tryptophan.
    Patmas MA
    N J Med; 1992 Apr; 89(4):285-6. PubMed ID: 1603435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan).
    Silver RM; Ludwicka A; Hampton M; Ohba T; Bingel SA; Smith T; Harley RA; Maize J; Heyes MP
    J Clin Invest; 1994 Apr; 93(4):1473-80. PubMed ID: 8163652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology of potential association between L-tryptophan ingestion and eosinophilia-myalgia syndrome.
    Daniels SR; Hudson JI; Horwitz RI
    J Clin Epidemiol; 1995 Dec; 48(12):1413-27; discussion 1429-40. PubMed ID: 8543957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eosinophilia-myalgia syndrome: patient status 2-4 years after onset.
    Pincus T
    J Rheumatol Suppl; 1996 Oct; 46():19-24; discussion 24-5. PubMed ID: 8895178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies with 1,1'-ethylidenebis(tryptophan), a contaminant associated with L-tryptophan implicated in the eosinophilia-myalgia syndrome.
    Sidransky H; Verney E; Cosgrove JW; Latham PS; Mayeno AN
    Toxicol Appl Pharmacol; 1994 May; 126(1):108-13. PubMed ID: 8184420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eosinophilia-myalgia syndrome: a recent syndrome serving as an alert to new diseases ahead.
    Sidransky H
    Mod Pathol; 1994 Sep; 7(7):806-10. PubMed ID: 7824518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome.
    Williamson BL; Tomlinson AJ; Mishra PK; Gleich GJ; Naylor S
    Chem Res Toxicol; 1998 Mar; 11(3):234-40. PubMed ID: 9544622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eosinophilia-myalgia syndrome not associated with the ingestion of nutritional supplements.
    Clauw DJ; Flockhart DA; Mullins W; Katz P; Medsger TA
    J Rheumatol; 1994 Dec; 21(12):2385-7. PubMed ID: 7699648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tryptophan-induced lung disease: an immunophenotypic, immunofluorescent, and electron microscopic study.
    Tazelaar HD; Myers JL; Strickler JG; Colby TV; Duffy J
    Mod Pathol; 1993 Jan; 6(1):56-60. PubMed ID: 8426858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Movement disorders in the eosinophilia-myalgia syndrome: tremor, myoclonus, and myokymia.
    Kaufman LD; Kaufman MA; Krupp LB
    J Rheumatol; 1995 Jan; 22(1):157-60. PubMed ID: 7699663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eosinophilia myalgia syndrome: absence of immunoglobulin reactivity suggests a cellular rather than humoral mechanism.
    Villanova M; De Clerck LS; Cras P; Guazzi GC; Martin JJ
    Acta Neurol Belg; 1994; 94(3):200-4. PubMed ID: 7976226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A refined symptom-based approach to diagnose pulmonary tuberculosis in children.
    Marais BJ; Gie RP; Hesseling AC; Schaaf HS; Lombard C; Enarson DA; Beyers N
    Pediatrics; 2006 Nov; 118(5):e1350-9. PubMed ID: 17079536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Head and neck manifestations of eosinophilia-myalgia syndrome.
    Levine B; Lanza DC; Ficco A; Freundlich B
    Ann Otol Rhinol Laryngol; 1995 Feb; 104(2):90-9. PubMed ID: 7857025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation.
    Smith MJ; Garrett RH
    Inflamm Res; 2005 Nov; 54(11):435-50. PubMed ID: 16307217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Eosinophilia-myalgia syndrome. The clinical spectrum expands].
    Schnabel A; Gross WL
    Z Rheumatol; 1992; 51(1):1-2. PubMed ID: 1574930
    [No Abstract]   [Full Text] [Related]  

  • 39. Negotiating the diagnostic uncertainty of contested illnesses: physician practices and paradigms.
    Swoboda DA
    Health (London); 2008 Oct; 12(4):453-78. PubMed ID: 18818275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eosinophilia-myalgia syndrome and fasciitis with an active alveolitis.
    Chauhan D; Mengel CE
    Kans Med; 1993 Jun; 94(6):175-7. PubMed ID: 8355447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.